Incyte: Pivotal Phase 3 Data Showing Significant Improvement

Data served as basis for recent FDA approval of ruxolitinib cream (Opzelura) 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older Fifty-two

Related Keywords

Delaware , United States , Japan , Ohio , American , Erica Cech , Catalina Loveman , David Rosmarin , Christine Chiou , Jim Lee , Group Vice , Drug Administration , Department Of Dermatology At Tufts Medical Center , Exchange Commission , Us Food Drug Administration , American Academy Of Dermatology , European Medicines Agency , Maruho Co Ltd , Incyte Corporation , New England Journal , Vitiligo Area Scoring Index , Group Vice President , Inflammation Autoimmunity , American Academy , Vice Chair , Tufts Medical , Mississippi River , Full Prescribing Information , Boxed Warning , Medication Guide , Controlled Trials , Ruxolitinib Cream , Incyte , Pivotal , Hase , Data , Showing , Significant , Improvements , Racial , Total , Body , Repigmentation , Ruxolitinib , Cream , Opzelura , Vitiligo , Published , England , Journal , Medicine ,